Results 71 to 80 of about 22,562,840 (346)

Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study

Haemophilia, 2018
The THUNDER study provides an analysis of treatment patterns and outcomes in UK patients with severe or moderate haemophilia A (SHA/MHA) in 2015.
M. Scott, H. Xiang, D. Hart, B. Palmer, P. Collins, D. Stephensen, C. S. Sima, C. Hay   +7 more
semanticscholar   +1 more source

Advances on Albumin‐Based Carriers for Anticancer Drug Delivery

Advanced NanoBiomed Research, EarlyView.
This study systematically classifies the drug delivery modes of albumin by examining the characteristics of its surface‐active groups and internal binding sites. It provides an in‐depth analysis of various drug delivery strategies and their corresponding targeting mechanisms.
Ruoli Zhou, Rongbin Zhong, Zhonghui Luo, Hua Wei, Cui‐Yun Yu   +4 more
wiley   +1 more source

Living, Caring, Learning – The power of qualitative research in bleeding disorders care: One voice, from soloist to choir

The Journal of Haemophilia Practice
With over three decades of nursing experience, Simon reflects on his experience as a research nurse at the Oxford Haemophilia and Thrombosis Centre at a time of huge change for haemophilia care and treatment.
Fletcher Simon
doaj   +1 more source

How to discuss gene therapy for haemophilia? A patient and physician perspective

Haemophilia, 2019
Gene therapy has the potential to revolutionise treatment for patients with haemophilia and is close to entering clinical practice. While factor concentrates have improved outcomes, individuals still face a lifetime of injections, pain, progressive joint
Wolfgang A. Miesbach, B. O’Mahony, N. Key, M. Makris   +3 more
semanticscholar   +1 more source

Techno‐Economic Analysis of Membrane‐Based Purification Platforms for AAV Vector Production

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Technologies for large‐scale manufacturing of viral vectors for gene therapies, such as tangential flow filtration and membrane chromatography, are under development. In these early stages of process development, techno‐economic analyses are useful for identifying membrane properties yielding the greatest impact on process performance. In this
Juan J. Romero, Eleanor W. Jenkins, Jacob I. Monroe, S. Ranil Wickramasinghe, Xianghong Qian, Dibakar Bhattacharyya, Scott M. Husson   +6 more
wiley   +1 more source

Haemophilia care in Europe:a survey of 19 countries [PDF]

, 2011
In 2009, a questionnaire was circulated to 19 national haemophilia patient organizations in Europe affiliated to the European Haemophilia Consortium (EHC) and the World Federation of Hemophilia (WFH) to seek information about the organization of ...
Giangrande, P.L.F., Noone, D., O'Mahony, B., Prihodova, L.   +3 more
core   +1 more source

Blood clot inspired pore‐gradient nanofiber sponge with “outer filtration” and “inner adsorption” bifunction for rapid stop of uncontrolled hemorrhage

BMEMat, EarlyView.
In this study, by mimicking the nanofiber structure and netting blood cells function of fibrin network in blood clots, we developed a novel bioinspired quaternized chitosan nanofiber sponge with distinct blood cell filtration and blood plasma absorption bifunction for rapid hemostasis.
Fujin Zhou, Yong Yang, Yixuan Li, Ruolin Cao, Zheng Chen, Zhi Wang, Naiwen Tan, Lei Tian, Botao Song   +8 more
wiley   +1 more source

Diagnosis of von Willebrand disease in Argentina: a single institution experience [PDF]

, 2017
von Willebrand disease (VWD) is the most common autosomal bleeding disorder, mostlyinherited as dominant trait. VWD is due to deficiency/abnormality of von Willebrand factor (VWF).
Blanco, Alicia Noemi, Kempfer, Ana Catalina, Lazzari, María Ángela, Paiva Palomino, Juvenal Hernán, Sánchez Luceros, Analía Gabriela, Woods, Adriana Inés   +5 more
core   +1 more source

Plasma levels of IL-1β and IL-37 in patients with severe haemophilia

Journal of International Medical Research, 2020
Objective Haemophilia A and B are disorders caused by the lack of clotting factors VIII and IX, respectively. Repeated bleeding into the same joint leads to haemophilic arthropathy (HA).
Pei-Chin Lin, Shyh-Shin Chiou, Wan-Yi Hsu, Yu-Mei Liao, Shih-Pien Tsai, Hsiu-Lan Su, Ping-Tao Lu, Yu-Hsin Tseng   +7 more
doaj   +1 more source

Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline

Haemophilia, 2019
Assay discrepancies can occur with laboratory monitoring of FVIII and FIX replacement therapy, particularly for the extended half‐life products. This guideline collates current published data and provides advice on appropriate choice of assays for ...
E. Gray, S. Kitchen, A. Bowyer, P. Chowdary, P. Jenkins, P. Murphy, S. Platton, A. Riddell, W. Lester   +8 more
semanticscholar   +1 more source